EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma

Seiichi Okabe iD, Yuya Arai, Yuko Tanaka, Akihiko Gotoh

Cancer Reports · 2025

DOI: 10.1002/cnr2.70249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Seiichi Okabe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Bridged Bicyclo Compounds, Heterocyclic, Triazoles, Hydrazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma ( MM ) is a blood cancer marked by the abnormal clonal growth of plasma cells. Hypoxia plays a critical role in the progression and treatment resistance of MM .

Aims

This study investigates the expression of B‐cell/CLL lymphoma 2 (BCL2) family genes. We also investigated the activity of BCL2 and exportin‐1 (XPO1) inhibitors and the potential therapeutic synergy of venetoclax and selinexor under hypoxic conditions. Methods and Results Analysis of publicly available datasets revealed hypoxia‐induced upregulation of BCL2 and BCL2 ‐like 11 ( BCL2L11 ) , while BCL2 ‐associated agonist of cell death ( BAD ) expression was suppressed. Venetoclax, a selective BCL2 inhibitor, demonstrated enhanced cytotoxicity and increased caspase‐3/7 activity under hypoxic conditions. Selinexor exhibited potent anti‐myeloma effects, including dose‐dependent reductions in cell viability and increased apoptotic activity. Combining selinexor with venetoclax under hypoxia produced anti‐myeloma effects, significantly reducing cell viability, increasing apoptosis, and disrupting the mitochondrial membrane potential. This combination effectively overcame resistance in bortezomib‐resistant MM cells and demonstrated efficacy in primary plasma cell leukemia ( PCL ) samples.

Conclusion

These findings highlight the potential of selinexor and venetoclax combination therapy to exploit hypoxia‐induced vulnerabilities in MM cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBridged Bicyclo Compounds, HeterocyclicTriazolesHydrazinesSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansCell Line, TumorProto-Oncogene Proteins c-bcl-2ApoptosisDrug SynergismCell SurvivalGene Expression Regulation, NeoplasticDrug Resistance, Neoplasm

Stichwörter der Autor:innen

BCL2hypoxiamyelomaselinexorvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicselinexorTriazolesHydrazinesSulfonamidesProto-Oncogene Proteins c-bcl-2BCL2 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Tokyo Medical University, Tokyo, Japan.

ORCID-Profile: Seiichi Okabe

Zitieren

APA

Okabe, S., Arai, Y., Tanaka, Y., & Gotoh, A. (2025). Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma. Cancer Reports. https://doi.org/10.1002/cnr2.70249

Vancouver

Okabe S, Arai Y, Tanaka Y, Gotoh A. Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma. Cancer Reports. 2025. doi:10.1002/cnr2.70249

BibTeX
@article{Okabe2025,
  author = {Okabe, Seiichi and Arai, Yuya and Tanaka, Yuko and Gotoh, Akihiko},
  title = {Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70249}
}
Kostenlos starten →